Chao Zeng1,2, Maureen Dubreuil3,4, Marc R LaRochelle5, Na Lu2, Jie Wei2, Hyon K Choi2, Guanghua Lei1, Yuqing Zhang2,3. 1. Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China. 2. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. 3. Boston University School of Medicine, Boston, Massachusetts. 4. VA Boston Healthcare System, Boston, Massachusetts. 5. Clinical Addiction Research and Education Unit, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts.
Abstract
Importance: An American Academy of Orthopaedic Surgeons guideline recommends tramadol for patients with knee osteoarthritis, and an American College of Rheumatology guideline conditionally recommends tramadol as first-line therapy for patients with knee osteoarthritis, along with nonsteroidal anti-inflammatory drugs. Objective: To examine the association of tramadol prescription with all-cause mortality among patients with osteoarthritis. Design, Setting, and Participants: Sequential, propensity score-matched cohort study at a general practice in the United Kingdom. Individuals aged at least 50 years with a diagnosis of osteoarthritis in the Health Improvement Network database from January 2000 to December 2015, with follow-up to December 2016. Exposures: Initial prescription of tramadol (n = 44 451), naproxen (n = 12 397), diclofenac (n = 6512), celecoxib (n = 5674), etoricoxib (n = 2946), or codeine (n = 16 922). Main Outcomes and Measures: All-cause mortality within 1 year after initial tramadol prescription, compared with 5 other pain relief medications. Results: After propensity score matching, 88 902 patients were included (mean [SD] age, 70.1 [9.5] years; 61.2% were women). During the 1-year follow-up, 278 deaths (23.5/1000 person-years) occurred in the tramadol cohort and 164 (13.8/1000 person-years) occurred in the naproxen cohort (rate difference, 9.7 deaths/1000 person-years [95% CI, 6.3-13.2]; hazard ratio [HR], 1.71 [95% CI, 1.41-2.07]), and mortality was higher for tramadol compared with diclofenac (36.2/1000 vs 19.2/1000 person-years; HR, 1.88 [95% CI, 1.51-2.35]). Tramadol was also associated with a higher all-cause mortality rate compared with celecoxib (31.2/1000 vs 18.4/1000 person-years; HR, 1.70 [95% CI, 1.33-2.17]) and etoricoxib (25.7/1000 vs 12.8/1000 person-years; HR, 2.04 [95% CI, 1.37-3.03]). No statistically significant difference in all-cause mortality was observed between tramadol and codeine (32.2/1000 vs 34.6/1000 person-years; HR, 0.94 [95% CI, 0.83-1.05]). Conclusions and Relevance: Among patients aged 50 years and older with osteoarthritis, initial prescription of tramadol was associated with a significantly higher rate of mortality over 1 year of follow-up compared with commonly prescribed nonsteroidal anti-inflammatory drugs, but not compared with codeine. However, these findings may be susceptible to confounding by indication, and further research is needed to determine if this association is causal.
Importance: An American Academy of Orthopaedic Surgeons guideline recommends tramadol for patients with knee osteoarthritis, and an American College of Rheumatology guideline conditionally recommends tramadol as first-line therapy for patients with knee osteoarthritis, along with nonsteroidal anti-inflammatory drugs. Objective: To examine the association of tramadol prescription with all-cause mortality among patients with osteoarthritis. Design, Setting, and Participants: Sequential, propensity score-matched cohort study at a general practice in the United Kingdom. Individuals aged at least 50 years with a diagnosis of osteoarthritis in the Health Improvement Network database from January 2000 to December 2015, with follow-up to December 2016. Exposures: Initial prescription of tramadol (n = 44 451), naproxen (n = 12 397), diclofenac (n = 6512), celecoxib (n = 5674), etoricoxib (n = 2946), or codeine (n = 16 922). Main Outcomes and Measures: All-cause mortality within 1 year after initial tramadol prescription, compared with 5 other pain relief medications. Results: After propensity score matching, 88 902 patients were included (mean [SD] age, 70.1 [9.5] years; 61.2% were women). During the 1-year follow-up, 278 deaths (23.5/1000 person-years) occurred in the tramadol cohort and 164 (13.8/1000 person-years) occurred in the naproxen cohort (rate difference, 9.7 deaths/1000 person-years [95% CI, 6.3-13.2]; hazard ratio [HR], 1.71 [95% CI, 1.41-2.07]), and mortality was higher for tramadol compared with diclofenac (36.2/1000 vs 19.2/1000 person-years; HR, 1.88 [95% CI, 1.51-2.35]). Tramadol was also associated with a higher all-cause mortality rate compared with celecoxib (31.2/1000 vs 18.4/1000 person-years; HR, 1.70 [95% CI, 1.33-2.17]) and etoricoxib (25.7/1000 vs 12.8/1000 person-years; HR, 2.04 [95% CI, 1.37-3.03]). No statistically significant difference in all-cause mortality was observed between tramadol and codeine (32.2/1000 vs 34.6/1000 person-years; HR, 0.94 [95% CI, 0.83-1.05]). Conclusions and Relevance: Among patients aged 50 years and older with osteoarthritis, initial prescription of tramadol was associated with a significantly higher rate of mortality over 1 year of follow-up compared with commonly prescribed nonsteroidal anti-inflammatory drugs, but not compared with codeine. However, these findings may be susceptible to confounding by indication, and further research is needed to determine if this association is causal.
Authors: Daniel H Solomon; Jeremy A Rassen; Robert J Glynn; Katie Garneau; Raisa Levin; Joy Lee; Sebastian Schneeweiss Journal: Arch Intern Med Date: 2010-12-13
Authors: Marie L Tørring; Anders Riis; Steffen Christensen; Reimar W Thomsen; Peter Jepsen; Jens Søndergaard; Henrik T Sørensen Journal: Br J Clin Pharmacol Date: 2007-10-08 Impact factor: 4.335
Authors: A D Beaulieu; P M Peloso; B Haraoui; W Bensen; G Thomson; J Wade; P Quigley; J Eisenhoffer; Z Harsanyi; A C Darke Journal: Pain Res Manag Date: 2008 Mar-Apr Impact factor: 3.037
Authors: Jie Wei; Nancy E Lane; Marcy B Bolster; Maureen Dubreuil; Chao Zeng; Devyani Misra; Na Lu; Hyon K Choi; Guanghua Lei; Yuqing Zhang Journal: J Bone Miner Res Date: 2020-02-05 Impact factor: 6.741
Authors: Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary Journal: Healthcare (Basel) Date: 2021-03-16
Authors: Chungsoo Kim; Seng Chan You; Jenna M Reps; Jae Youn Cheong; Rae Woong Park Journal: J Am Med Inform Assoc Date: 2021-06-12 Impact factor: 4.497
Authors: J Wei; M J Wood; M Dubreuil; G Tomasson; M R LaRochelle; C Zeng; N Lu; J Lin; H K Choi; G Lei; Y Zhang Journal: Osteoarthritis Cartilage Date: 2019-10-16 Impact factor: 6.576